Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Defining Interactions Between the Genome, Epigenome, and the Environment in Inflammatory Bowel Disease: Progress and Prospects.

Noble AJ. et al, (2023), Gastroenterology

Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research

Alexander JL. et al, (2023), Gut

The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study.

Sun Y. et al, (2023), Am J Gastroenterol

Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease

Shubhakar A. et al, (2023), Journal of Crohn's and Colitis

Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.

Chen J. et al, (2023), Aliment Pharmacol Ther

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.

Louis E. et al, (2023), Lancet Gastroenterol Hepatol

Bi-directional Mendelian randomization analysis provides evidence for the causal involvement of dysregulation of CXCL9, CCL11 and CASP8 in the pathogenesis of ulcerative colitis.

Chen J. et al, (2022), J Crohns Colitis

Long-term temporal stability of peripheral blood DNA methylation profiles in patients with inflammatory bowel disease.

Joustra V. et al, (2022), Cell Mol Gastroenterol Hepatol

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.

Adams A. et al, (2022), Gut

Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.

Selim R. et al, (2022), Lancet Gastroenterol Hepatol

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.

Wellens J. et al, (2022), Gut, 71, 1919 - 1922

Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome.

Kalla R. et al, (2022), J Crohns Colitis

Systematic Review and Meta-analysis of Peripheral Blood DNA methylation studies in Inflammatory Bowel Disease.

Joustra V. et al, (2022), J Crohns Colitis

Patient Reported Outcomes: the ICHOM Standard Set for inflammatory bowel disease in real life practice helps quantify deficits in current care.

Wong D. et al, (2022), J Crohns Colitis

Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.

Serra EG. et al, (2022), Nat Commun, 13

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis

Hart A. et al, (2022), United European Gastroenterology Journal, 10, 485 - 495

BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE

Wellens J. et al, (2022), GASTROENTEROLOGY, 162, S278 - S278

PERIPHERAL BLOOD DNA METHYLATION BIOMARKERS ACCURATELY PREDICT CLINICAL- AND ENDOSCOPIC RESPONSE TO VEDOLIZUMAB IN A REAL-LIFE COHORT OF CROHNS DISEASE PATIENTS

Joustra VW. et al, (2022), GASTROENTEROLOGY, 162, S794 - S794

TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE

Wong S-Y. et al, (2022), GASTROENTEROLOGY, 162, S1004 - S1005

WITHDRAWAL OF INFLIXIMAB OR ANTI-METABOLITE THERAPY IN CROHN'S DISEASE PATIENTS IN SUSTAINED REMISSION ON COMBINATION THERAPY: A RANDOMIZED UNBLINDED CONTROLLED TRIAL (SPARE)

Louis E. et al, (2022), GASTROENTEROLOGY, 162, S216 - S216

Load More

Include forthcoming?